Skip to main content Help with accessibility Skip to main navigation

July 2022 updates to the website

The website has now been updated following July's LSCMMG

The following guidelines have been added/updated:

Primary care PPI review guideline - added

Varenicline position statement - updated

Asthma desktop guideline - added

Amiodarone shared care guideline - updated

Lipid pathway guideline - added

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Paliperidone 6 monthly - As a treatment option for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products

Romosozumab - Severe osteoporosis (NICE TA791)

Filgotinib - For treating moderately to severely active ulcerative colitis (NICE TA792)

Faricimab - For treating diabetic macular oedema (NICE TA799)

Faricimab - For treating wet age-related macular degeneration (NICE TA800)